Finasteride Pharmacokinetics: How This 5-Alpha Reductase Inhibitor Moves Through Your Body

How Finasteride Works: Mechanism of Action

Finasteride is a competitive, irreversible inhibitor of the type II isoenzyme of 5-alpha reductase. This is the enzyme that converts testosterone to dihydrotestosterone (DHT) in the prostate, liver, and hair follicles of the scalp. By blocking this conversion, finasteride reduces circulating DHT concentrations by roughly 70% at the 1 mg dose used for androgenetic alopecia (AGA) and by up to 70 to 75% at the 5 mg dose approved for benign prostatic hyperplasia (BPH) 1.

The distinction between finasteride and dutasteride matters here. Finasteride selectively inhibits type II 5-alpha reductase, while dutasteride inhibits both type I and type II isoenzymes 2. Type II predominates in the prostate and hair follicle dermal papilla. Type I is found primarily in sebaceous glands and liver. This selectivity shapes finasteride's pharmacodynamic profile: it does not suppress DHT as completely as a dual inhibitor, but it targets the tissues most relevant to AGA and BPH with fewer off-target hormonal effects.

The binding is irreversible. Once finasteride attaches to the enzyme-NADPH complex, the enzyme is permanently inactivated. New enzyme must be synthesized to restore 5-alpha reductase activity. This explains why the pharmacodynamic duration of finasteride far exceeds what its 5-to-6-hour plasma half-life would predict 3.

Absorption: Oral Bioavailability and Rate

Finasteride's absolute oral bioavailability is approximately 80%, according to data in the FDA-approved prescribing information 4. The drug is absorbed rapidly from the gastrointestinal tract, reaching maximum plasma concentrations (Cmax) within 1 to 2 hours of ingestion.

Food does not meaningfully alter the rate or extent of absorption. A pharmacokinetic study in healthy volunteers demonstrated that co-administration with a high-fat meal did not change the area under the curve (AUC) or Cmax to a clinically significant degree 4. Patients can take finasteride with or without food. This is a practical advantage for daily adherence.

After a single 1 mg oral dose in healthy young men, mean Cmax values reach approximately 9.2 ng/mL. With the 5 mg BPH dose, peak concentrations scale roughly proportionally 5. Steady-state plasma concentrations are achieved within 3 to 5 days of daily dosing, and accumulation is minimal. The mean trough concentration at steady state with 1 mg daily is approximately 3.5 ng/mL.

Distribution: Where Finasteride Goes After Absorption

The volume of distribution (Vd) of finasteride at steady state is approximately 76 liters 4. This relatively large Vd indicates meaningful tissue distribution beyond the plasma compartment.

Protein binding sits at roughly 90%. Finasteride binds primarily to albumin and, to a lesser extent, alpha-1-acid glycoprotein. No evidence suggests clinically relevant displacement interactions with other highly protein-bound drugs, though formal displacement studies are limited 4.

Finasteride crosses the blood-brain barrier. Cerebrospinal fluid (CSF) concentrations have been detected, though at levels substantially lower than plasma 6. This CNS penetration is pharmacologically relevant because 5-alpha reductase also catalyzes the synthesis of neuroactive steroids such as allopregnanolone and tetrahydrodeoxycorticosterone in the brain. Researchers have proposed that inhibition of neurosteroid synthesis may contribute to certain reported neuropsychiatric side effects, although the clinical significance remains debated 6.

Semen distribution has been studied in the context of reproductive safety. In men taking 1 mg finasteride daily, finasteride concentrations in semen were measured at a median of approximately 0.26 ng/mL, representing an estimated maximum exposure to a female partner of approximately 0.00076 mg per ejaculate. This is roughly 750 times lower than the 1 mg daily dose and considered unlikely to have pharmacological effects 4.

Metabolism: Hepatic Processing via CYP3A4

The liver is finasteride's primary site of metabolism. Cytochrome P450 3A4 (CYP3A4) is the principal enzyme responsible for biotransformation, with a minor contribution from CYP3A5 4. Two metabolites have been identified in human plasma:

1. t-Butyl side chain monohydroxylated metabolite (the omega-hydroxy metabolite)
2. Monocarboxylic acid metabolite (formed by further oxidation of the omega-hydroxy intermediate)

Both metabolites possess no more than 20% of the 5-alpha reductase inhibitory activity of the parent compound 4. For practical purposes, these are considered pharmacologically inactive. The parent drug accounts for the entirety of the clinical effect.

Drug Interaction Potential

Because finasteride is a CYP3A4 substrate, co-administration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) could theoretically increase finasteride plasma levels. However, the prescribing information states that no clinically meaningful drug interactions have been identified in formal studies 4. Finasteride does not appear to inhibit or induce CYP enzymes at therapeutic doses. It does not affect the pharmacokinetics of antipyrine, digoxin, propranolol, theophylline, or warfarin.

Dr. Keith Kaufman, who led the key 5-year AGA trial for Merck, noted in his 1998 publication: "Finasteride 1 mg/day was well tolerated with no clinically significant laboratory abnormalities or drug interactions observed over the study period" 1.

This low interaction potential is one reason finasteride remains a first-line agent for AGA in men who are often taking other medications, particularly older men on polypharmacy regimens for BPH.

Elimination: Half-Life, Clearance, and Excretion

The terminal elimination half-life of finasteride is 5 to 6 hours in men aged 18 to 60 years 4. In men over 70, the half-life extends to approximately 8 hours, consistent with age-related declines in hepatic clearance.

Plasma clearance is approximately 165 mL/min 4. Following an intravenous dose of radiolabeled finasteride, excretion occurs through two routes:

• Feces: 57% of the administered dose (primarily as metabolites)
• Urine: 39% of the administered dose (as metabolites)

Virtually no unchanged finasteride is recovered in urine, confirming that hepatic metabolism, not renal excretion, is the primary elimination pathway 4.

The Half-Life vs. Pharmacodynamic Duration Paradox

This is where clinicians often misunderstand finasteride. A 5-to-6-hour half-life suggests the drug should be cleared from the body within about 30 hours (roughly five half-lives). Yet DHT suppression persists for days after discontinuation.

The explanation is enzyme kinetics. Finasteride binds irreversibly to type II 5-alpha reductase. Once the drug is eliminated from plasma, the enzyme remains inactivated. DHT levels only recover as new enzyme protein is synthesized, a process with a turnover half-life estimated at 14 to 30 days 3. After stopping finasteride, serum DHT returns to baseline over approximately 2 weeks, not the 30 hours that plasma kinetics alone would predict.

The Endocrine Society's 2019 clinical practice guideline on androgen therapy acknowledges that 5-alpha reductase inhibitors have pharmacodynamic durations that far outlast their plasma presence, a factor that must be considered when counseling patients about the timeline for side-effect resolution after discontinuation 7.

Special Populations: Renal and Hepatic Impairment

Renal Impairment

No dose adjustment is required for patients with renal impairment, including those with creatinine clearance as low as 9 mL/min 4. Because less than 1% of finasteride is excreted renally as unchanged drug, impaired kidney function does not meaningfully alter drug exposure.

Hepatic Impairment

Formal pharmacokinetic studies in patients with hepatic impairment are limited. The FDA label notes that finasteride is extensively metabolized in the liver, so patients with liver function abnormalities could have elevated plasma levels 4. No specific dose-adjustment guidelines exist for hepatic impairment. Clinicians should exercise caution in patients with significant liver disease, particularly those with Child-Pugh class B or C cirrhosis, as the impact on finasteride clearance in this population has not been formally characterized.

Elderly Patients

As noted above, the half-life extends to approximately 8 hours in men over 70. Despite this, the AUC after a single 5 mg dose increased by only 20 to 30% in elderly men compared with younger volunteers, and no dose adjustment is recommended 4. The 5 mg dose for BPH and the 1 mg dose for AGA apply across age groups.

Dose-Response Pharmacokinetics: 1 mg vs. 5 mg

The dose-response curve for DHT suppression is not linear. A 1 mg dose suppresses serum DHT by approximately 65 to 70%. Increasing to 5 mg adds only an additional 5 to 8 percentage points of suppression, bringing total DHT reduction to approximately 70 to 75% 5.

This near-plateau effect explains why 1 mg is the standard AGA dose. The Kaufman et al. study (N=1,553) demonstrated that 1 mg daily for up to 5 years increased hair count by a mean of 277 hairs (1-inch target area on the vertex scalp) compared with placebo, a difference that was statistically significant (P<0.001) and clinically visible on standardized photographs 1.

Plasma pharmacokinetics are dose-proportional across the 1 to 100 mg range, meaning AUC and Cmax scale linearly with dose 4. The nonlinear dose-response for DHT reflects enzyme-level saturation, not absorption or distribution limitations. At 1 mg, finasteride already occupies a large fraction of available type II 5-alpha reductase binding sites.

Scalp Tissue Pharmacokinetics

Scalp DHT concentrations, not just serum levels, drive AGA pathology. A study by Drake et al. measured DHT in scalp biopsy specimens from men taking finasteride 1 mg daily for 42 days. Scalp DHT fell by 64.1% compared with placebo (P<0.001), while scalp testosterone increased by 40% as the conversion pathway was blocked 8. The increase in local testosterone did not offset the reduction in DHT signaling at the androgen receptor, because DHT has roughly 3 to 10 times greater binding affinity for the androgen receptor than testosterone 9.

This tissue-level pharmacokinetic data helps explain why finasteride works for hair loss despite incomplete systemic DHT suppression. The drug effectively reduces the androgen signal at the follicle even though circulating DHT is only reduced by about two-thirds.

Pharmacogenomics: SRD5A2 Polymorphisms

The gene encoding type II 5-alpha reductase (SRD5A2) has known polymorphisms, including the V89L variant (rs523349), which reduces enzyme activity by 30 to 40% in homozygous carriers 10. Men with lower baseline 5-alpha reductase activity may have different responses to finasteride, though prospective pharmacogenomic trials stratified by SRD5A2 genotype are lacking.

CYP3A4 polymorphisms could also theoretically alter finasteride metabolism. The CYP3A4*22 reduced-function allele (rs35599367) has a minor allele frequency of approximately 5 to 7% in European populations 11. Carriers could have higher finasteride exposure, though this has not been studied directly. No current guideline recommends pharmacogenomic testing before prescribing finasteride.

Monitoring and Clinical Implications

The FDA label for finasteride 1 mg (Propecia) does not mandate routine laboratory monitoring 4. For the 5 mg BPH formulation (Proscar), clinicians should be aware that finasteride reduces serum PSA by approximately 50% within 6 months of treatment. The American Urological Association recommends doubling the measured PSA value in men taking finasteride to estimate the "true" PSA for cancer screening purposes 12.

Serum DHT can be measured to confirm pharmacodynamic response, but this is rarely done in routine AGA management. In cases of suspected non-response, a DHT level drawn at trough (just before the next dose) that has not declined by at least 50% from baseline may suggest non-adherence or atypical metabolism.

After discontinuation, serum DHT returns to pretreatment levels within approximately 14 days, and any hair regrowth achieved with finasteride begins to reverse within 6 to 12 months 1.